Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Periodontal disease is a chronic inflammatory disease of the tissues surrounding the teeth and is one of the leading causes of tooth loss. Sanative therapy (ST) is a non-surgical procedure that allows for removal of bacteria from the deep pockets that form around teeth and is the frontline treatment for periodontal disease. Post-ST, patients require ongoing maintenance appointments to maintain their oral health, though whether risk factors for periodontal disease remain a predictor of periodontal health post-ST has not been comprehensively investigated. Risk factors to be examined include physical activity, exercise, sedentary time, flavonoid intake, protein intake, BMI, sex, age, smoking status, and number of sites with periodontal probing depth (PPD) ≥ 4mm at baseline.
Description: This is a routine clinical measure of periodontal health (measured in mm)
Measure: Probing depth Time: At maintenance appointment (present day)Description: This is a routine clinical measure of periodontal health (measured in mm)
Measure: Probing depth Time: Pre-sanative therapyDescription: This is a routine clinical measure of periodontal health (measured in mm)
Measure: Probing depth Time: 8-12 weeks post-sanative therapyDescription: This is a clinical measure of inflammation and represented as the percent of bleeding sites that are measured at 6 sites per tooth
Measure: Bleeding on probing Time: At maintenance appointment (present day) and retrospectively from the clinical record from the time of sanative therapy (5 to 10 years ago) onwardsDescription: This is a clinical measure of inflammation and represented as the percent of bleeding sites that are measured at 6 sites per tooth
Measure: Bleeding on probing Time: Pre-sanative therapyDescription: This is a clinical measure of inflammation and represented as the percent of bleeding sites that are measured at 6 sites per tooth
Measure: Bleeding on probing Time: 8-12 weeks post-sanative therapyDescription: Will be measured as the number of teeth lost due to periodontal disease
Measure: Tooth Loss Time: At maintenance appointment (present day) and retrospectively from the clinical record from the time of sanative therapy (5 to 10 years ago) onwardsDescription: Will be measured as the number of teeth lost due to periodontal disease
Measure: Tooth Loss Time: Pre-sanative therapyDescription: Will be measured as the number of teeth lost due to periodontal disease
Measure: Tooth Loss Time: 8-12 weeks post-sanative therapyDescription: The patient's plaque index= the number of plaque-containing surfaces divided by the total number of available surfaces. The minimum plaque index would be 0% which represents no tooth surfaces that contain plaque/ The maximum plaque index would be 100%, which represents all surfaces of the patient's teeth containing plaque.
Measure: O'Leary Index of Plaque Control Time: At maintenance appointment (present day) and retrospectively from the clinical record from the time of sanative therapy (5 to 10 years ago) onwardsDescription: The patient's plaque index= the number of plaque-containing surfaces divided by the total number of available surfaces. The minimum plaque index would be 0% which represents no tooth surfaces that contain plaque/ The maximum plaque index would be 100%, which represents all surfaces of the patient's teeth containing plaque.
Measure: O'Leary Index of Plaque Control Time: Pre-sanative therapyDescription: The patient's plaque index= the number of plaque-containing surfaces divided by the total number of available surfaces. The minimum plaque index would be 0% which represents no tooth surfaces that contain plaque/ The maximum plaque index would be 100%, which represents all surfaces of the patient's teeth containing plaque.
Measure: O'Leary Index of Plaque Control Time: 8-12 weeks post-sanative therapyDescription: Patients will self-report their height and weight in an online questionnaire. This information will be used to calculate BMI which is a known risk factor of periodontal disease.
Measure: Body Mass Index (BMI) Time: Patients will complete this in an online questionnaire at present day (baseline).Description: This questionnaire measures, at one time point, self-reported exercise habits for the past 7 days. This questionnaire includes 4 items and has been combined with the International Physical Activity Questionnaire. Name of score: Weekly leisure activity score; Minimum score: 0 units and Maximum score: 24 units or more and defined as "active". A higher score indicates a better outcome.
Measure: Godin Leisure Time Exercise Questionnaire Time: Patients will complete this in an online questionnaire at present day (baseline).Description: This questionnaire measures, at one time point, self-reported physical activity and sedentary behavior habits. It contains 27 items and has been combined with the Godin Leisure Time Exercise Questionnaire and modified version of the indices of estrogen exposure questionnaire in an online format. They will self-report their physical activity and sedentary behavior for the past 7 days. Name of score: Weekly physical activity score; Minimum score: 1 and defined as "low physical activity" and Maximumscore: 3 and defined as "high physical activity". A higher score indicates a better outcome.
Measure: International Physical Activity Questionnaire (IPAQ) Time: Patients will complete this online questionnaire at present day (baseline).Description: Flavonoid and protein intake will be measured with the automated self-administered dietary intake (ASA-24) questionnaire. This is an online food recall that patients will complete three times, reporting on their dietary intake from the last 24 hours.
Measure: Flavonoid and protein intake Time: Patients will report their dietary intake at present day (baseline) for the past 24 hours. This will be done three times for three separate dates.Description: The indices of estrogen exposure questionnaire will be used to determine LEE using the estimated lifetime estrogen exposure (ELEE) model. The ELEE reflects the reproductive span, comprising a woman's time between age at menarche and age at menopause (or age at recruitment minus age at menarche for pre-menopausal women) minus 1 year for each pregnancy and duration of breastfeeding, calculated at the time at recruitment.
Measure: Lifetime estrogen exposure (LEE) Time: Patients will complete this online questionnaire at present day (baseline).Description: Intakes of specific dietary supplements and tea will be measured using a dietary supplement and tea intake questionnaire.
Measure: Dietary supplement and tea intake Time: Patients will complete this questionnaire online prior to their maintenance appointmentDescription: Patients will be asked interview questions about changes to their dietary intake, physical activity and oral hygiene habits resulting from the COVID-19 pandemic
Measure: COVID-19 Interview questions Time: Patients will complete these interview questions during their one-on-one virtual meeting with a member of the research team at present day (baseline).Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports